Charlotte’s Web Holdings, Inc. (TSE:CWEB) just released its latest quarterly report and things are not looking great. It definitely looks like a negative result overall with revenues falling 13% short of analyst estimates at US$22m. Statutory losses were US$0.13 per share, 189% bigger than what the analysts expected. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there’s been a strong change in the company’s prospects, or if it’s business as usual. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.
View our latest analysis for Charlotte’s Web Holdings
After the latest results, the eight analysts covering Charlotte’s Web Holdings are now predicting revenues of US$98.0m in 2020. If met, this would reflect a satisfactory 7.6% improvement in sales compared to the last 12 months. The loss per share is expected to greatly reduce in the near future, narrowing 20% to US$0.35. Before this latest report, the consensus had been expecting revenues of US$111.4m and US$0.16 per share in losses. There’s been a definite change in sentiment in this update, with the analysts administering a notable cut to next year’s revenue estimates, while at the same time increasing their loss per share forecasts.
The average price target fell 8.0% to US$5.46, implicitly signalling that lower earnings per share are a leading indicator for Charlotte’s Web Holdings’ valuation. That’s not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. Currently, the most bullish analyst values Charlotte’s Web Holdings at US$10.00 per share, while the most bearish prices it at US$3.90. So we wouldn’t be assigning too much credibility to analyst price targets in this case, because there are clearly some widely different views on what kind of performance this business can generate. With this in mind, we wouldn’t rely too heavily the consensus price target, as it is just an average and analysts clearly have some deeply divergent views on the business.
Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. It’s clear from the latest estimates that Charlotte’s Web Holdings’ rate of growth is expected to accelerate meaningfully, with the forecast 7.6% revenue growth noticeably faster than its historical growth of 5.8% over the past year. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 34% per year. So it’s clear that despite the acceleration in growth, Charlotte’s Web Holdings is expected to grow meaningfully slower than the industry average.
The Bottom Line
The most important thing to take away is that the analysts increased their loss per share estimates for next year. On the negative side, they also downgraded their revenue estimates, and forecasts imply revenues will perform worse than the wider industry. Furthermore, the analysts also cut their price targets, suggesting that the latest news has led to greater pessimism about the intrinsic value of the business.
With that said, the long-term trajectory of the company’s earnings is a lot more important than next year. We have forecasts for Charlotte’s Web Holdings going out to 2023, and you can see them free on our platform here.
It is also worth noting that we have found 2 warning signs for Charlotte’s Web Holdings that you need to take into consideration.
This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email firstname.lastname@example.org.
Two Republicans resign from North Carolina election board
(Reuters) – Two Republicans resigned from the North Carolina State Board of Elections late on Wednesday, the panel said, citing concerns about a plan to settle a lawsuit over counting of absentee ballots in the Nov. 3 presidential election, among other issues.
Ken Raymond and David Black stepped down over a lawsuit filed by the North Carolina Alliance for Retired Americans against the five-member election board, it said in a statement that attached their letters of resignation.
“It is impossible to have true bipartisanship when both sides of the political aisle do not have the important and vital information needed to make the right decisions,” Raymond said in his letter.
Black referred to concerns over the witness requirement for absentee ballots.
“It was not my understanding that the cure would simply mean a affidavit, or cure document, would be sent to the voter for a confirmation that this ballot was their own,” he said.
The election officials had struck a tentative agreement on Tuesday to count any absentee ballots that arrive up to nine days after the Nov. 3 election, so long as they are postmarked by election day.
“The unanimous agreement of the five-member State Board regarding the proposed settlement came after counsel to all board members from agency attorneys and litigation counsel before and during last week’s closed session meeting,” the board said in its statement.
Raymond and Black are both former chairmen of county election boards in North Carolina, where President Donald Trump this month urged residents to try to vote twice in the election, once by mail and once in person.
Trump won North Carolina and its 15 electoral votes by 3.6 percentage points over Clinton in 2016. The Southern state has gone consistently Republican in presidential elections since 1980, with the exception of Obama’s victory there in 2008.
That makes Democratic challenger Joe Biden’s slight lead in recent polls in the state a significant worry for the president.
(Reporting by Aishwarya Nair in Bengaluru; Editing by Clarence Fernandez)
MSNBC’s Chris Hayes warns of a coup after Trump says he wants to ‘Get rid of ballots’ [Video]
On All In With Chris Hayes Wednesday night, Hayes had a dire warning for the American people following a press conference earlier in the day in which President Trump refused to commit to a peaceful transfer of power if he were to lose the presidential election in November, and even spoke of getting rid of ballots.
When asked if he would commit to a peaceful transfer of power, Trump answered, “Well, we’re gonna have to see what happens. You know that I’ve been complaining about the ballots. And the ballots are a disaster.” “I understand that, but people are rioting,” The reporter pushed. “Do you commit to making sure that there’s peaceful transferral of power?” Trump replied, “We wanna have—Get rid of the ballots and we’ll have a very peaceful—There won’t be a transfer, frankly. There’ll be a continuation.”
Trump received immediate backlash, including from Republican senator Mitt Romney.
Fundamental to democracy is the peaceful transition of power; without that, there is Belarus. Any suggestion that a president might not respect this Constitutional guarantee is both unthinkable and unacceptable.
— Mitt Romney (@MittRomney) September 24, 2020
“A chilling moment, I gotta say,” Hayes said in response to Trump’s answer. “I don’t know any other way to say it. The President of the United States threatening violence to stay in power. Sounds weird coming out of my mouth but that’s what happened.” He later added, “What the president is doing here is the most explicit that he has been about his plans for this election. He’s plotting in open, in public, repeatedly, a coup to steal the election and hold onto power.”
In recent months, Trump has continually spread unfounded conspiracies about mail-in voting; his campaign has sued states that expanded mail-in voting due to the ongoing coronavirus pandemic; and his hand-picked postmaster general has taken steps to hamper the mail-in voting process, including the removal of over 700 mail-sorting machines. Hayes believes the plan is to sow distrust in the mail-in voting process, and to slow the arrival of mail-in ballots, and that Trump will try to use this to his advantage.
“He will take advantage of something called the ‘Red Mirage’ where more Republican votes come in first because those people voted in person, making it look like Trump is ahead on election night,” Hayes said. “And then he will attempt to use the courts to delay something called the ‘Blue Shift,’ which is just the counting of more heavily Democratic mail-in votes. They’re all the same votes. They’re all just getting counted at different times.”
Trump, along with most senate Republicans, is pushing to fill the Supreme Court vacancy left by the passing of Ruth Bader Ginsberg, and he has openly admitted, with a strong conservative majority on the Supreme Court, that he is counting on them to decide the election, no matter the vote count.
“He will try to use the courts, then, to invalidate as many as those mail-in ballots…as he can. Remember, this is why today he refused to commit to a peaceful transfer of power, the mail-in ballots,” Hayes said. “Get rid of those ballots, he said. Those mail-in ballots are also the reason the president says, keeps saying, that he is counting on the courts, the federal courts, to help him win. He’s not going to wait for the ballots to be counted. He’s saying it.”
Even without filling the vacant seat on the Supreme Court, conservatives hold a 5-3 majority. But Hayes believes Republicans want to fill it before the election because, as he put it, “Apparently they do not trust Chief Justice John Roberts to be enough of a hack to corruptly hand them the White House.”
Hayes pointed out other ways Trump may try to “steal” the election, and concluded that the only way to make sure that doesn’t happen is record voter turnout.
All In With Chris Hayes airs weeknights at 8 p.m. on MSNBC.
Watch Chris Cuomo slam Trump’s ‘epic hypocrisy’ for changing his views on election year SCOTUS appointments:
Read more from Yahoo Entertainment:
AstraZeneca still waiting for FDA decision to resume U.S. trial
3 “Strong Buy” Stocks That Are Flirting With a Bottom
In the investing game, it’s not only about what you buy; it’s about when you buy it. One of the most common pieces of advice thrown around the Street, “buy low” is touted as a tried-and-true tactic.Sure, the strategy seems simple. Stock prices naturally fluctuate on the basis of several factors like earnings results and the macro environment, amongst others, with investors trying to time the market and determine when stocks have hit a bottom. In practice, however, executing on this strategy is no easy task.On top of this, given the volatility that has ruled the markets over the last few weeks, how are investors supposed to gauge when a name is flirting with a bottom? That’s where the Wall Street pros come in.These expert stock pickers have identified three compelling tickers whose current share prices land close to their 52-week lows. Noting that each is set to take back off on an upward trajectory, the analysts see an attractive entry point. Using TipRanks’ database, we found out that the analyst consensus has rated all three a Strong Buy, with major upside potential also on tap.Progenity (PROG)Offering clear and actionable genetic results, Progenity specializes in providing testing services. The company started trading on Nasdaq in June and saw its shares tumbling 44% since then. With shares changing hands for $8.11, several members of the Street recommend pulling the trigger before it heats up.Piper Sandler analyst Steven Mah points out that even against the backdrop of COVID-19, PROG managed to deliver with its Q2 2020 performance. “We are encouraged by the recovery in late Q2 2020 with 75,000 accessioned tests (~79,000 in Q1 2020), driven by noninvasive prenatal testing (NIPT) and carrier screening,” the analyst noted. Expounding on this, Mah stated, “Progenity did not provide guidance, but June test volumes of ~28,000 were strong (Q1 2020 monthly average was ~26,000) which we believe showcases the durability of its reproductive tests and the success that Progenity has in co-marketing and attaching carrier screening to the more essential NIPT. Of note, despite the pandemic disruptions, Progenity was able to maintain its leading pre-COVID test turnaround times.”Additionally, health insurer Aetna is temporarily extending coverage of average-risk NIPT until year-end as a result of the pandemic, with the American College of Obstetricians and Gynecologists (ACOG) also expected to endorse average-risk in the future given its clinical utility, in Mah’s opinion.Reflecting another positive, the fourth generation NIPT (single-molecule counting assay) test was able to measure fetal fraction, a key milestone according to Mah, and will continue to be developed into 2021. As the technology could potentially be applied to DNA, RNA, epigenetic markers and proteins for additional clinical applications such as oncology, the analyst is looking forward to the completion of the preeclampsia verification in Q4 2020 and a possible 2H21 launch. “We believe preeclampsia (~2.3 billion serviceable market) is a major differentiator for Progenity, allowing them to cross-sell across the full-continuum of reproductive testing,” the analyst added.If that wasn’t enough, PROG signed its first GI Precision Medicine partnership agreement with a top-20 Pharma company in August. The Oral Biotherapeutic Delivery System (OBDS), an ingestible drug and device combination designed to precisely deliver biologics systemically through a needle-free liquid jet injection into the submucosal tissues of the small intestine, is set to be utilized as part of the collaboration. Mah commented, “We believe Progenity can sign additional Pharma deals and look forward to the newsflow coming out on this front.”To sum it all up, Mah said, “We believe Progenity shares are undervalued given the robust recovery in the core testing business and multiple upcoming growth catalysts.”To this end, Mah rates PROG an Overweight (i.e. Buy) along with a $17 price target. Should his thesis play out, a twelve-month gain of 105% could potentially be in the cards. (To watch Mah’s track record, click here)Are other analysts in agreement? They are. Only Buy ratings, 4, in fact, have been issued in the last three months. Therefore, the message is clear: PROG is a Strong Buy. Given the $13.33 average price target, shares could climb 60% higher in the next year. (See PROG stock analysis on TipRanks)Tactile Systems Technology (TCMD)Developing at-home therapy devices, Tactile Systems Technology wants to provide new treatments for lymphedema, which occurs when the lymphatic system is impaired, disrupting normal transport of fluid within the body, and chronic venous insufficiency. Down 52% year-to-date, its $32.67 share price lands close to its $29.47 52-week low. Thus, with business trends improving, the Street is pounding the table.Writing for Canaccord, analyst Cecilia Furlong acknowledges that the pandemic has hampered the company, with COVID-19 weighing on both volumes and sales. In the second half of March, volumes were down 50% compared to the first half of the month, and TCMD’s patient volumes in April and May remained challenged. That being said, trends started to improve at the end of May.“Going forward, given the vast majority of TCMD’s clinician customers practice in outpatient or office-based settings, we remain positive on TCMD’s ability to demonstrate better insulation against COVID impacts and likely experience a greater bounce-back relative to overall med-tech volume trends, with TCMD further benefitting from its expanding using of technology to remotely engage with clinicians and support patients,” Furlong explained.The analyst added, “Furthermore, recent trends among some providers to prescribe Flexitouch (an advanced intermittent pneumatic compression device to self-manage lymphedema and nonhealing venous leg ulcers) earlier along the therapy process, as a means to reduce in-person contact, could provide upside near term, as well as potentially transition to a longer-term tailwind.”On top of this, Furlong is also optimistic about new CEO Dan Reuvers and the reprioritization of the company’s investment and market development efforts. TCMD will shift focus away from its acquired Airwear product line, with it redirecting investments toward its Flexitouch and Entre (a pneumatic compression device used to assist in the home management of chronic swelling and venous ulcers associated with lymphedema and chronic venous insufficiency) products.“Given significant under-penetration in the lymphedema/phlebolymphedema market targeted by Flexitouch alongside the large patient population with limited treatment options today targeted by the firm’s Head & Neck platform, we view the combination of education and clinical data as key to further developing and penetrating these markets… Going forward, we expect management to continue to compile a broad base of clinical data to support reimbursement and drive broad adoption,” Furlong commented.All of this prompted Furlong to keep a Buy rating and $62 price target on the stock. This target conveys her confidence in TCMD’s ability to soar 90% in the next year. (To watch Furlong’s track record, click here)In general, other analysts are on the same page. With 3 Buy ratings and 1 Hold, the word on the Street is that TCMD is a Strong Buy. The $62.33 average price target brings the upside potential to 91%. (See TCMD stock analysis on TipRanks)uniQure N.V. (QURE)Last but not least we have uniQure, which delivers curative gene therapies that could potentially transform the lives of patients. Even though shares have fallen 44% year-to-date to $40, not much higher than its 52-week low of $36.20, multiple analysts still have high hopes.Representing SVB Leerink, 5-star analyst Joseph Schwartz acknowledges that shares struggled after news broke of its collaboration and licensing agreement with CSL Behring for AMT-061, QURE’s gene therapy for Hemophilia B, he argues the “shareholder base turnover is likely now complete as investors and QURE shift focus to next-in-line AMT-130, its AAV5 gene therapy for Huntington’s Disease (HD).”Schwartz further added, “With the M&A premium now out of the stock, we see the QURE’s current level as an attractive buying opportunity for those investors interested in the company’s up and coming CNS gene therapies, internal manufacturing, and robust intellectual property and knowhow.”Looking more closely at the agreement with CSL Behring, QURE will be tasked with the completion of the pivotal Phase 3 HOPE-B trial as well as the manufacturing process validation and manufacturing supply of AMT-061.According to management, 26-week Factor IX (FIX) data from all 54 patients enrolled in the trial remains on track, and topline data from the pivotal trial is still slated to read out by YE20. It should be mentioned that in a Phase 2b dose-confirmation study, QURE reported 41% FIX activity out to one year. Additionally, Schwartz points out that with HOPE-B progressing as planned, QURE has continued its manufacturing process validation work ahead of the anticipated BLA/MAA submissions in the U.S. and EU in 2021.On top of this, as part of the deal, QURE is eligible to receive more than $2 billion including a $450 million upfront cash payment, $1.6 billion in regulatory and commercial milestones and double-digit royalties ranging up to the low-twenties percentage of net product sales.“With a strengthened cash position, QURE is well funded to rapidly advance CNS assets including AMT-130 (AAV5 gene therapy for Huntington’s Disease (HD)) and AMT-150 (AAV gene therapy for Spinocerebellar Ataxia Type 3/SCA3)…We continue to believe that as QURE’s CNS pipeline assets mature, the company could once again be an attractive partner to larger biopharma companies that have recently acquired many publicly traded gene therapy platforms with substantial manufacturing capabilities,” Schwartz noted.Everything that QURE has going for it convinced Schwartz to reiterate an Outperform (i.e. Buy) rating. Along with the call, he attached a $67 price target, suggesting 68% upside potential from current levels. (To watch Schwartz’s track record, click here)What does the rest of the Street have to say? 9 Buys and 3 Holds have been issued in the last three months, so the consensus rating is a Strong Buy. In addition, the $69.89 average price target indicates 75% upside potential. (See QURE stock analysis on TipRanks)To find good ideas for beaten-down stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
- PSG preparing to pull out of negotiations to sign Dele Alli on season-long loan
- Two Republicans resign from North Carolina election board
- MSNBC’s Chris Hayes warns of a coup after Trump says he wants to ‘Get rid of ballots’ [Video]
- AstraZeneca still waiting for FDA decision to resume U.S. trial
- Rumors Suggest a Remake of Metal Gear Solid is in Development
- Pat Riley not going anywhere, and I’m not replacing him with Heat if he does
- ByteDance just asked China for permission to export TikTok’s technology as it tries to finalize a deal with the US government
- “Don’t Cry Sour Grapes After the Fight” – Legendary Boxer Goes off on Deontay Wilder
- Arsenal win at Leicester to set up possible clash with Liverpool
- Conjoined twins are successfully separated after being locked in embrace
Entertainment4 days ago
Danish TV show ‘Ultra Strips Down’ records kids eyeing naked adults
Sports News3 weeks ago
Fantasy Football Auction Draft strategy: Tips, advice for spending your 2020 player budget wisely
Sports News3 weeks ago
NBA 2K21 Cover Star Damian Lillard Reveals His Issues With the Game
Sports News3 days ago
Fantasy Football Buy-Low, Sell-High Stock Watch: Leonard Fournette, Stefon Diggs among movers heading into Week 3
Sports News3 weeks ago
NBA playoff bracket 2020: Updated standings, seeds & results from each round
Sports News2 weeks ago
NFL Analyst Takes a Cheeky Dig on Browns Stars Odell Beckham Jr. and Baker Mayfield
Tech2 days ago
iOS 14 basics: how to add widgets to your iPhone’s home screen
Sports4 days ago
What just happened? Danny Lee six-putts 18th green, withdraws from U.S. Open